Author

Thiago J. Borges

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Marginal Zone B Cell Targeting Limits Alloantigen Availability to Follicular Dendritic Cells and Mitigates Antibody-Mediated Rejection.

Chronic antibody-mediated rejection is a leading cause of allograft loss, with limited therapies that effectively target humoral immunity. Current immunosuppressive regimens primarily target T cells, leaving a critical gap in strategies to suppress antibody-driven rejection. Marginal zone (MZ) B cells are innate-like c...

R. B. Gassen, Kaifeng Liu, Yoshikazu Ganchiku et al. · American Journal of Transpla... · 0 citations

#gene editing Sep 2026

Porcine kidney xenotransplantation as a bridge to allotransplantation: a first-in-human study.

This case shows that porcine kidney xenotransplantation can provide prolonged renal support and be discontinued without clinically significant allosensitisation or zoonotic infection.

L. Riella, Thiago J. Borges, Ivy A. Rosales et al. · The Lancet · 2 citations

Open access Jul 2026

Targeted immunosuppression with a tissue-selective PD-1 agonist prevents rejection of transplanted hearts 2308742

Systemic immunosuppression to prevent allograft rejection or treat autoimmune disease can risk infection and malignancy. To uncouple therapeutic immunosuppression from systemic toxicity, we engineered Location-Specific T-cell Inhibitory Molecules (LoSTIMs), Fc-silent bispecific antibodies that activate PD-1 and i...

J. Torchia, Minxue Liao, Nitzan Shakartzi Kaminsky et al. · Journal of Immunology · 0 citations